-
Brady Clark, Ph.D.
Chief Executive Officer (CEO) & Founder
-
Remmick So, M.Sc.
Chief Operating Officer (COO)
-
Corwin Nycholat, Ph.D.
Chief Scientific Officer (CSO)
-
Fengyang Yan, Ph.D.
Vice President of Chemistry (VP)
-
Zhonghong Gan, Ph.D.
Director of Carbohydrate Chemistry
-
Dennis Whitfield, Ph.D.
Scientific Advisor
The National Research Council (NRC) of Canada
The NRC, established in 1916, is renowned for its pioneering contributions across diverse disciplines in support of scientific and industrial research in Canada. Its inaugural laboratories were established at the historical flagship facility, Steacie Institute for Molecular Science (SIMS) on Sussex Drive in Ottawa, Canada's capital. Research conducted at NRC-SIMS has resulted in significant discoveries, fostering groundbreaking research and innovation in Canada, and contributions by several Nobel laureates.
Situated within the NRC, our company benefits from the proximity to this prestigious institution, enhancing our surroundings with a rich scientific heritage and fostering a dynamic environment that encourages collaboration and supports cutting-edge research initiatives.
Our History
The Beginning
Sussex Research Laboratories Inc. was founded by Dr. Brady Clark as a spin-off company of the NRC. His vision was to create a company that specialized in carbohydrate-based products and services to fulfill the unmet needs of the burgeoning glycobiology field.
-
Strategic Alliances
We forged key strategic alliances with Sigma-Aldrich, Johnson & Johnson and Genentech. These partnerships enabled companies to modernize their portfolio by introducing quality carbohydrate intermediates.
-
Introduction of Glycosylated Ligands
We shifted focus from products tailored for chemists to tools designed for biochemists, biologists, immunologists, and medical researchers. This transition was driven by the more complex needs of these fields, particularly in glycobiology.
Glycoamino Acids Development
We began the strategic development of glycoamino acid building blocks to facilitate the synthesis of glycopeptides and glycoproteins via solid/solution-phase peptide synthesis. These products marked our debut in clinical trials, in collaboration with GMP manufacturer Bachem.
Vice President of Chemistry
Dr. Fengyang Yan (former NRC researcher under Dr. Dennis Whitfield) was promoted to Vice President, assuming oversight of the entire chemistry division.
-
Introduction of Glycopeptides
As one of the first and largest producers of glycoamino acids, we leveraged our synthetic expertise to produce glycopeptides, aiming to serve researchers in proteomics, glycobiology, cancer research and vaccine development.
-
Implementing Enzymatic Synthesis
In collaboration with the NRC, we began using carbohydrate processing enzymes and developed chemoenzymatic methods to access complex carbohydrate structures - a long-term partnership that remains active today.
-
Glycosylated Lipid Nanoparticle (LNP) Development
We began development of glycoPEGylated lipids for use as LNP tissue-targeted carriers, designed to deliver therapeutic payloads such as RNA and proteins, contributing to advancements in targeted drug delivery systems.
-
Lipoglycopeptides as Cosmetic Actives
We patented a lipidated glycopeptide (Glycolastin™) for cosmetic applications, garnering significant attention from major beauty brands such as P&G, Estée Lauder and Croda. These cosmetic actives showcased the company’s innovation in skincare solutions.
Glycoconjugates & Early-Stage Vaccine Development
With expertise in polysaccharide chemistry and protein conjugation, we established ourselves as a key player in producing immunogens for antibody and early-stage vaccine development. Our collaborations have included industry leaders such as BioNTech, Pfizer, GSK, Bharat Biotech and Vaxcyte.
-
Chief Operating Officer
Remmick So was promoted as COO to oversee the entirety of the company's operations and in the planning and execution of business strategies. Since joining the company in 2013, she played pivotal roles in the development of Glycolastin™ and led the bio-analytical team in the development of a broad-spectrum pneumococcal conjugate vaccine (PCV).
-
Chief Scientific Officer
Dr. Corwin Nycholat joined our team following a 15-year career at The Scripps Research Institute (TSRI), where he worked under renowned glycobiologist, James C. Paulson. He also served as Core Director of the Carbohydrate Synthesis Core, funded by the National Heart, Lung, and Blood Institute (NHLBI) for the Program of Excellence in Glycosciences.
Sussex Research Laboratories (USA) Inc.
We have strategically expanded our presence by establishing a subsidiary in San Diego, California. This move has enabled us to seize new growth opportunities and foster innovation, ensuring improved access to our products and services while enhancing our impact in the industry.
